News

Verana Health’s newly launched Qdata Cataract offers a comprehensive dataset to improve outcomes, reduce complications and enhance IOL technology.

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment.

Carl Zeiss Meditec plans to launch the ZEISS RDP in select countries throughout 2025

A machine learning model using treated astigmatism and other nuanced inputs can significantly improve the accuracy and personalization of arcuate keratotomy planning

The Virtual Eye Simulation Analyzer is an AI-driven digital twin of the human eye designed to model aging and personalize presbyopia treatment across the lifecycle.

New research links genetic risk for schizophrenia to retinal thinning, suggesting early indicators of the disorder may be found in retinal morphology.

The research team from the University of Cincinnati surveyed 42 patients 50 years of age and older at Hoxworth Eye Clinic

ZEISS Research Data Platform is a cloud-based, AI-driven solution designed to transform ophthalmic research workflows.

Explore the challenges and strategies of private practice management, focusing on financial sustainability and patient care in today's healthcare landscape.

The clearance expands its existing label from patients aged 4 to 7 years to patients aged 4 to under 13 years.

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and healthcare institutions.

Retina World Congress 2025 unites global retina experts in Fort Lauderdale to explore cutting-edge research, surgical techniques, and patient care advancements.

4D-150 is a potential backbone therapy that is designed to provide multiyear sustained delivery of anti-VEGF (aflibercept and anti–VEGF-C) to be targeted to the retina with a single, well-tolerated intravitreal injection.

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor.

Shehzad Batliwala, DO, known to his patients as Dr. Shehz, appeared on the ASCRS Foundation Symposium, where he discussed performing refractive surgery in low-resource, high-risk areas.

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment

A novel vitrectomy device shows promising safety and efficacy in the targeted removal of symptomatic vitreous opacities in pseudophakic eyes

Prevent Blindness has declared May the second annual inherited retinal disease and genetic testing month, offering free resources on education and other awareness efforts.

A large international study reported a genetic link between schizophrenia and retinal status.

Alex Hacopian, MD, highlights how a recent ambispective study demonstrated strong visual acuity outcomes and patient satisfaction following bilateral implantation of an advanced presbyopia-correcting intraocular lens.

Researchers evaluate key measures for tracking disease progression in Usher syndrome type 2–related retinal degeneration

STAR-GLOBAL is an extension trial of the initial EU clinical trials investigating the long term safety and efficacy of MINIject in patients with glaucoma with up to 5 years of follow up.

Topcon Healthcare appoints Daniela Ferrara, MD, PhD, as Chief Medical Officer to enhance AI-driven ocular imaging and advance digital healthcare solutions.

Lisa Nijm, MD, says preoperative osmolarity testing can help clinicians manage patient expectations and improve surgical results.